Satomi Onoue Selected Research

Arg(15,20,21)-Leu(17)- vasoactive intestinal peptide-GRR

11/2010	Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.
1/2010	Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
9/2009	Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability.
12/2004	Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
12/2004	Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21, L17]-VIP-GRR (IK312532).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Satomi Onoue Research Topics

Disease

20	Phototoxic Dermatitis (Phototoxicity) 12/2021 - 03/2008
15	Asthma (Bronchial Asthma) 01/2013 - 12/2004
12	Inflammation (Inflammations) 03/2018 - 05/2004
12	Chronic Obstructive Pulmonary Disease (COPD) 01/2012 - 05/2004
5	Achlorhydria (Hypochlorhydria) 04/2018 - 04/2012
3	Photoallergic Dermatitis (Photoallergy) 12/2021 - 04/2008
3	Idiopathic Pulmonary Fibrosis 01/2020 - 03/2013
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2020 - 06/2017
3	Overactive Urinary Bladder (Overactive Bladder) 05/2019 - 01/2016
3	Pain (Aches) 01/2018 - 01/2011
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 08/2013 - 06/2012
3	Lung Diseases (Lung Disease) 09/2007 - 12/2004
2	Heart Failure 01/2021 - 11/2008
2	Colitis 07/2018 - 06/2017
2	Pneumonia (Pneumonitis) 06/2013 - 01/2010
2	Insulinoma 01/2011 - 11/2008
2	Body Weight (Weight, Body) 01/2011 - 12/2009
2	Hypoglycemia (Reactive Hypoglycemia) 12/2009 - 02/2005
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 04/2009 - 03/2009
2	Ischemia 08/2002 - 07/2002
1	Cryptosporidiosis 12/2021
1	Hyperuricemia 07/2021
1	Retinal Dystrophies 06/2021
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 06/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Cicatrix (Scar) 01/2020
1	Hypertriglyceridemia 05/2018
1	Hypothermia 02/2017
1	Drug-Related Side Effects and Adverse Reactions 01/2015

Drug/Important Bio-Agent (IBA)

22	Pharmaceutical PreparationsIBA 12/2021 - 12/2004
11	Neutral RedIBA 12/2021 - 03/2008
8	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2016 - 08/2008
8	PowdersIBA 08/2013 - 06/2009
7	AntigensIBA 03/2018 - 01/2011
6	tranilastIBA 07/2018 - 02/2010
5	Biomarkers (Surrogate Marker)IBA 01/2016 - 06/2009
5	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 06/2012 - 09/2007
5	Arg(15,20,21)-Leu(17)- vasoactive intestinal peptide-GRRIBA 11/2010 - 12/2004
4	Peptides (Polypeptides)IBA 12/2021 - 08/2002
4	pirfenidoneIBA 01/2020 - 03/2013
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2020 - 08/2009
4	DNA (Deoxyribonucleic Acid)IBA 03/2013 - 10/2008
3	Peroxidase (Myeloperoxidase)IBA 07/2018 - 06/2009
3	Omeprazole (Prilosec)FDA LinkGeneric 04/2018 - 04/2012
3	SolutionsIBA 06/2017 - 01/2011
3	Dipyridamole (Persantine)FDA LinkGeneric 01/2013 - 04/2012
3	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 01/2011 - 08/2002
3	Glucagon (Glukagon)FDA Link 12/2009 - 07/2004
2	Biological ProductsIBA 07/2018 - 07/2002
2	Meloxicam (Mobic)FDA LinkGeneric 01/2018 - 02/2013
2	Ethanol (Ethyl Alcohol)IBA 06/2017 - 02/2017
2	Dosage Forms (Dosage Form)IBA 01/2016 - 08/2009
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2013 - 08/2009
2	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 09/2011 - 09/2010
2	Anti-Allergic Agents (Antiallergic Agents)IBA 02/2011 - 02/2010
2	SmokeIBA 11/2010 - 12/2004
2	OvalbuminIBA 01/2010 - 06/2009
2	Glucose (Dextrose)FDA LinkGeneric 12/2009 - 02/2005
2	Hormones (Hormone)IBA 12/2009 - 02/2005
2	Protease Inhibitors (Protease Inhibitor)IBA 08/2009 - 05/2004
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 06/2009 - 11/2008
2	saw palmetto extractIBA 04/2009 - 03/2009
2	Fatty Acids (Saturated Fatty Acids)IBA 10/2008 - 03/2008
1	Clofazimine (Lamprene)FDA Link 12/2021
1	Uric Acid (Urate)IBA 07/2021
1	2- (2- (4- (dibutylamino)phenyl)ethenyl)- 3- carboxymethylbenzothiazoliumIBA 06/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021
1	Lisinopril (Prinivil)FDA LinkGeneric 01/2021
1	fesoterodine FDA Link 05/2019
1	Corn Oil (Oil, Corn)IBA 05/2018
1	Fenofibrate (CiL)FDA LinkGeneric 08/2017
1	AcidsIBA 06/2017
1	Itraconazole (Sporanox)FDA LinkGeneric 01/2017
1	Muscarinic M3 ReceptorIBA 01/2017
1	imidafenacinIBA 01/2017
1	Solifenacin Succinate FDA Link 01/2016
1	Muscarinic AntagonistsIBA 01/2016
1	Leucine (L-Leucine)FDA Link 01/2016
1	Mannitol (Osmitrol)FDA LinkGeneric 01/2016
1	Plant ExtractsIBA 08/2015
1	Ketoprofen (Orudis)FDA LinkGeneric 08/2015
1	benzophenoneIBA 08/2015
1	Cardiovascular AgentsIBA 01/2015
1	TeaIBA 01/2015
1	PolymersIBA 01/2013
1	SaltsIBA 01/2013
1	Delayed-Action PreparationsIBA 06/2012
1	Bleomycin (Blenoxane)FDA LinkGeneric 06/2012
1	CollagenIBA 06/2012
1	3,4,11- trihydroxy- 2- (hydroxymethyl)- 8- (4- hydroxyphenyl)- 3,4,4a,11b- tetrahydro- 2H,10H- pyrano(2',3'- 4,5)furo(3,2- g)chromen- 10- oneIBA 01/2012
1	EmulsionsIBA 01/2012
1	ErythritolIBA 01/2012
1	Amyloid (Amyloid Fibrils)IBA 09/2011
1	flavoneIBA 09/2011

Therapy/Procedure

8	Oral Administration 10/2021 - 09/2009
6	Therapeutics 02/2011 - 12/2004
4	Respiratory Therapy (Therapy, Respiratory) 01/2016 - 08/2009
3	Dry Powder Inhalers 01/2011 - 08/2009
1	Anesthesia 01/2020
1	Enema (Enemas) 06/2017